Skip to content

Remote Dynamic Monitoring and Management after Valvular Heart Disease Intervention Treatment Based on Smart Wearable Devices

Research on the lifetime Management and Optimization of Diagnosis and Treatment Technologies for Valvular Heart Disease(Sub-topics) Remote Dynamic Monitoring and Management after Valvular Heart Disease Intervention Treatment Based on Smart Wearable Devices

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600123691
Enrollment
Unknown
Registered
2026-04-28
Start date
2026-04-13
Completion date
Unknown
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic valve stenosis

Interventions

Smart Monitoring Group:Use of CAD FLOW wearable ultrasound patch for monitoring carotid and jugular vein blood flow
clinicians make clinical decisions (e.g., valve deployment timing, fluid management, vasopressor adjustments) based on ultrasound patch data
Control Group:No neck ultrasound patch monitoring
surgical procedures, fluid management, and vasopressor adjustments based on individual clinical experience and routine indicators such as ECG, invasive arterial pressure, and echocardiography

Sponsors

The Sixth Medical Center, Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of severe aortic valve stenosis: According to the "2017 Guidelines of the American Society of Echocardiography (ASE) on Non-invasive Assessment of Valve Stenosis", any one of the following criteria is met: the area of the aortic valve orifice (EOA) is less than 1.0 cm^2; The peak velocity of the aortic valve (AV-Vmax) is >=4.0 m/s; The mean transvalvular aortic valve pressure difference (PGmean) is >=40 mmHg. 2. Patients who, after assessment, meet the indications for transcatheter aortic valve replacement (TAVR) and are scheduled to undergo TAVR.

Exclusion criteria

Exclusion criteria: 1. Patients who are unwilling to accept registration and follow-up; 2. Patients with mental illness who could not cooperate with information collection and follow-up. 3. Patients with life expectancy less than 12 months due to non-cardiac diseases (such as cancer, liver disease, kidney disease or end-stage lung disease). 4. Persistent atrial fibrillation 5. Neck skin injury, excessive subcutaneous fat or pathological conditions affecting the quality of ultrasound signals (such as carotid artery stenosis > 70%, history of carotid artery stenting).

Design outcomes

Primary

MeasureTime frame
The mean transvalvular pressure gradient of the aortic valve at 24-48 hours after operation.;The peak velocity of aortic valve 24-48 hours after operation.;

Secondary

MeasureTime frame
The effective orifice area of aortic valve at 24-48 hours after operation;Cardiac ejection fraction at 24-48 hours after surgery;Incidence of perioperative complications;The treatment of the surgeon 's reference patch data and the changes of cervical arteriovenous blood flow waveforms and parameters before and after treatment were analyzed.;

Countries

China

Contacts

Public ContactWang Jing

The Sixth Medical Center, Chinese PLA General Hospital

wangjing121@126.com+86 134 6637 9798

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026